C4 Therapeutics (CCCC) Share-based Compensation (2019 - 2025)
Historic Share-based Compensation for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $4.6 million.
- C4 Therapeutics' Share-based Compensation fell 4799.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year decrease of 1604.76%. This contributed to the annual value of $29.7 million for FY2024, which is 891.13% up from last year.
- C4 Therapeutics' Share-based Compensation amounted to $4.6 million in Q3 2025, which was down 4799.0% from $5.0 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Share-based Compensation high stood at $8.9 million for Q1 2022, and its period low was $3.8 million during Q1 2021.
- Over the past 5 years, C4 Therapeutics' median Share-based Compensation value was $6.4 million (recorded in 2021), while the average stood at $6.5 million.
- In the last 5 years, C4 Therapeutics' Share-based Compensation soared by 321465.52% in 2021 and then crashed by 4799.0% in 2025.
- Quarter analysis of 5 years shows C4 Therapeutics' Share-based Compensation stood at $6.4 million in 2021, then grew by 8.91% to $6.9 million in 2022, then decreased by 8.09% to $6.4 million in 2023, then rose by 29.5% to $8.2 million in 2024, then plummeted by 44.23% to $4.6 million in 2025.
- Its last three reported values are $4.6 million in Q3 2025, $5.0 million for Q2 2025, and $5.5 million during Q1 2025.